438 related articles for article (PubMed ID: 27405665)
1. Therapeutic targeting of myeloid-derived suppressor cells involves a novel mechanism mediated by clusterin.
Zhou J; Donatelli SS; Gilvary DL; Tejera MM; Eksioglu EA; Chen X; Coppola D; Wei S; Djeu JY
Sci Rep; 2016 Jul; 6():29521. PubMed ID: 27405665
[TBL] [Abstract][Full Text] [Related]
2. Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs.
Bosiljcic M; Cederberg RA; Hamilton MJ; LePard NE; Harbourne BT; Collier JL; Halvorsen EC; Shi R; Franks SE; Kim AY; Banáth JP; Hamer M; Rossi FM; Bennewith KL
Breast Cancer Res; 2019 Sep; 21(1):103. PubMed ID: 31488209
[TBL] [Abstract][Full Text] [Related]
3. CD205
Fu C; Fu Z; Jiang C; Xia C; Zhang Y; Gu X; Zheng K; Zhou D; Tang S; Lyu S; Ma S
Cancer Sci; 2021 Mar; 112(3):1011-1025. PubMed ID: 33368883
[TBL] [Abstract][Full Text] [Related]
4. Distinct Role of CD11b
Wu SY; Chiang CS
Cells; 2019 Dec; 9(1):. PubMed ID: 31878276
[TBL] [Abstract][Full Text] [Related]
5. The mTOR signal regulates myeloid-derived suppressor cells differentiation and immunosuppressive function in acute kidney injury.
Zhang C; Wang S; Li J; Zhang W; Zheng L; Yang C; Zhu T; Rong R
Cell Death Dis; 2017 Mar; 8(3):e2695. PubMed ID: 28333137
[TBL] [Abstract][Full Text] [Related]
6. Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function.
Nam S; Kang K; Cha JS; Kim JW; Lee HG; Kim Y; Yang Y; Lee MS; Lim JS
J Leukoc Biol; 2016 Dec; 100(6):1273-1284. PubMed ID: 27601624
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of Ly6G
Heim CE; West SC; Ali H; Kielian T
Infect Immun; 2018 Dec; 86(12):. PubMed ID: 30249747
[TBL] [Abstract][Full Text] [Related]
8. CD11b+Gr-1+ myeloid-derived suppressor cells reduce atherosclerotic lesion development in LDLr deficient mice.
Foks AC; Van Puijvelde GH; Wolbert J; Kröner MJ; Frodermann V; Van Der Heijden T; Van Santbrink PJ; Boon L; Bot I; Kuiper J
Cardiovasc Res; 2016 Aug; 111(3):252-61. PubMed ID: 27234908
[TBL] [Abstract][Full Text] [Related]
9. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.
Schouppe E; Mommer C; Movahedi K; Laoui D; Morias Y; Gysemans C; Luyckx A; De Baetselier P; Van Ginderachter JA
Eur J Immunol; 2013 Nov; 43(11):2930-42. PubMed ID: 23878002
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptor 2 ligand and interferon-γ suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells.
Shime H; Maruyama A; Yoshida S; Takeda Y; Matsumoto M; Seya T
Oncoimmunology; 2017; 7(1):e1373231. PubMed ID: 29296526
[TBL] [Abstract][Full Text] [Related]
11. CD11b
Nachmany I; Bogoch Y; Sivan A; Amar O; Bondar E; Zohar N; Yakubovsky O; Fainaru O; Klausner JM; Pencovich N
FASEB J; 2019 May; 33(5):5967-5978. PubMed ID: 30730772
[TBL] [Abstract][Full Text] [Related]
12. Polysaccharide Agaricus blazei Murill stimulates myeloid derived suppressor cell differentiation from M2 to M1 type, which mediates inhibition of tumour immune-evasion via the Toll-like receptor 2 pathway.
Liu Y; Zhang L; Zhu X; Wang Y; Liu W; Gong W
Immunology; 2015 Nov; 146(3):379-91. PubMed ID: 26194418
[TBL] [Abstract][Full Text] [Related]
13. Expansion of CD11b(+)Ly6G (+)Ly6C (int) cells driven by medroxyprogesterone acetate in mice bearing breast tumors restrains NK cell effector functions.
Spallanzani RG; Dalotto-Moreno T; Raffo Iraolagoitia XL; Ziblat A; Domaica CI; Avila DE; Rossi LE; Fuertes MB; Battistone MA; Rabinovich GA; Salatino M; Zwirner NW
Cancer Immunol Immunother; 2013 Dec; 62(12):1781-95. PubMed ID: 24114144
[TBL] [Abstract][Full Text] [Related]
14. CD33
Sun Y; Shao J; Jiang F; Wang Y; Yan Q; Yu N; Zhang J; Zhang J; Li M; He Y
Am J Reprod Immunol; 2019 Jan; 81(1):e13067. PubMed ID: 30375700
[TBL] [Abstract][Full Text] [Related]
15. Visualization and quantification of
Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
[TBL] [Abstract][Full Text] [Related]
16. Tumor conditions induce bone marrow expansion of granulocytic, but not monocytic, immunosuppressive leukocytes with increased CXCR2 expression in mice.
Bian Z; Shi L; Venkataramani M; Abdelaal AM; Culpepper C; Kidder K; Liang H; Zen K; Liu Y
Eur J Immunol; 2018 Mar; 48(3):532-542. PubMed ID: 29120053
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of curcumin on myeloid-derived suppressor cells is requisite for controlling lung cancer.
Liu D; You M; Xu Y; Li F; Zhang D; Li X; Hou Y
Int Immunopharmacol; 2016 Oct; 39():265-272. PubMed ID: 27497194
[TBL] [Abstract][Full Text] [Related]
18. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers.
Kodumudi KN; Woan K; Gilvary DL; Sahakian E; Wei S; Djeu JY
Clin Cancer Res; 2010 Sep; 16(18):4583-94. PubMed ID: 20702612
[TBL] [Abstract][Full Text] [Related]
19. Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells.
Lee M; Park CS; Lee YR; Im SA; Song S; Lee CK
Arch Pharm Res; 2014; 37(9):1234-40. PubMed ID: 24748512
[TBL] [Abstract][Full Text] [Related]
20. mTOR masters monocytic myeloid-derived suppressor cells in mice with allografts or tumors.
Wu T; Zhao Y; Wang H; Li Y; Shao L; Wang R; Lu J; Yang Z; Wang J; Zhao Y
Sci Rep; 2016 Feb; 6():20250. PubMed ID: 26833095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
